What are T-cell costimulation inhibitor drugs?

T-cell costimulation inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting CD80/CD86). 2 are currently marketed, with 2 more in clinical development.

What are the marketed T-cell costimulation inhibitor drugs?

Marketed T-cell costimulation inhibitor drugs include abatacept infusion, IV Abatacept.

T-cell costimulation inhibitor

2 marketed 2 in Phase 3

This page covers all T-cell costimulation inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD80/CD86, CD80/CD86 (on antigen-presenting cells); CD28 (on T cells).

Targets

CD80/CD86 · CD80/CD86 (on antigen-presenting cells); CD28 (on T cells)

Marketed (2)

abatacept infusion · University of Minnesota · Immunology
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.
IV Abatacept · Rüdiger B. Müller · Immunology
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.

Phase 3 pipeline (2)

Abatacept (W12-W48) · University Hospital, Montpellier · Immunology
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.
PLA + MTX switched to ABA+ MTX, DB · Bristol-Myers Squibb · Immunology
Abatacept (ABA) is a T-cell costimulation inhibitor that blocks the interaction between antigen-presenting cells and T cells, reducing inflammatory immune responses when combined with methotrexate (MTX).